
    
      This study is designed to be multi-center, open-label, single-arm, prospective, phase II
      trial of patient with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients
      who previously treated with EGFR TKI and cytotoxic chemotherapy. Approximately 69 patients
      will be enrolled into the trial, and expected study duration is 48 months from Institutional
      Review Board(IRB) and Korea Ministry of Food and Drug Safety(MFDS) approval date.

      The study drug will be administered orally as one tablet(Gefitinib 250mg/ Erlotinib 150mg)
      once a day until disease progression or manifestation of unacceptable toxicity. The initial
      dose of the study drug daily can be reduced according to dose reduction criteria in protocol.
      A cycle of study treatment is defined as 28 days, and subjects will visit the site every 2
      cycles(56 days).
    
  